Balance Sheet
Cash Flow Statement
AcquisitionsAmortizationCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in IntangiblesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and Equipment
Growth Metrics
Income Statement
Others
Ratios

Astrazeneca (AZNCF) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Astrazeneca (AZNCF) over the last 15 years, with Q4 2025 value amounting to -$1.0 billion.

  • Astrazeneca's Capital Expenditures fell 4632.77% to -$1.0 billion in Q4 2025 from the same period last year, while for Dec 2025 it was -$2.8 billion, marking a year-over-year decrease of 4604.99%. This contributed to the annual value of -$2.8 billion for FY2025, which is 4604.99% down from last year.
  • Astrazeneca's Capital Expenditures amounted to -$1.0 billion in Q4 2025, which was down 4632.77% from -$686.0 million recorded in Q3 2025.
  • In the past 5 years, Astrazeneca's Capital Expenditures ranged from a high of $1.9 billion in Q4 2021 and a low of -$1.0 billion during Q4 2025
  • Its 5-year average for Capital Expenditures is -$289.5 million, with a median of -$335.0 million in 2021.
  • Its Capital Expenditures has fluctuated over the past 5 years, first soared by 1924.31% in 2021, then crashed by 7251.31% in 2025.
  • Quarter analysis of 5 years shows Astrazeneca's Capital Expenditures stood at $1.9 billion in 2021, then plummeted by 113.61% to -$253.0 million in 2022, then decreased by 6.72% to -$270.0 million in 2023, then plummeted by 162.22% to -$708.0 million in 2024, then plummeted by 46.33% to -$1.0 billion in 2025.
  • Its Capital Expenditures stands at -$1.0 billion for Q4 2025, versus -$686.0 million for Q3 2025 and -$659.0 million for Q2 2025.